The moonshot, The Cancer Letter's biggest area of coverage of 2016, continues into 2017.
As the New Year approaches, we are preparing to revamp our website and launch an app. The work on it is almost done—a January launch seems likely.
A federal judge ruled that Amgen Inc. cannot force me to answer questions related to a 2007 story that sparked a class action suit by investors and triggered a change in FDA regulations of erythropoiesis-stimulating agents.
2014 was a transformative year for The Cancer Letter.
